First treatment with Q-PRO[®] and integrated image management technology
The first treatment with the new generation of SpectraCure's Q-PRO[®] treatment system and the integrated image management technology has been performed at Memorial Sloan Kettering Cancer Center in New York. SpectraCure's new generation of the treatment system Q-PRO® and the integrated ultrasound image management technology from MedCom in Germany, has previously been approved by the […]
Skåne University Hospital in Malmö is included in the clinical trial for treatment of recurrent prostate cancer
SpectraCure AB (publ) has signed an agreement with Skåne University Hospital (Skånes Universitetssjukhus) in Malmö that will participate in the study for the treatment of recurrent prostate cancer using the company's proprietary system Q-PRO®. SpectraCure is developing a medical device for the treatment of recurrent prostate cancer. It is a focal therapy that can be […]
SpectraCure has registered the trademark Q-PRO[®]
SpectraCure AB (publ) has obtained trademark protection for Q-PRO[®], the name of the new generation system, in Europe and in the USA. Applications to register the trademark have been submitted in Australia, China and Japan. SpectraCure is developing a system for treatment of recurrent prostate cancer. The system is currently used in a clinical study […]
SpectraCure’s new treatment system has been approved in the UK for use in clinical trials
SpectraCure's new generation of treatment systems has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) for use in the ongoing clinical trial for the treatment of relapsing prostate cancer. The new treatment system has already been approved by the authorities in Canada and the USA, which means that the system is now approved […]
Patent regarding the new generation of treatment systems approved in Europe
SpectraCure's patent application relating to the technical solution in the new generation of treatment systems has been approved by the European Patent Office. The patent describes the technical solution that allows SpectraCure's treatment system to use the same optical fibers (light guide) to deliver the treatment light and to perform the measurements, to enable individual […]
SpectraCure’s CEO is leaving the company
Johan Folkunger has today informed the board that he is resigning from his position as CEO of SpectraCure. Johan Folkunger is leaving SpectraCure as a result of being offered, and having accepted, a new assignment as CEO of another company. Johan Folkunger has a notice period of six months and will continue to work during […]
Software for improved imaging technology is approved for use in clinical study in the US
MedCom GmbH's medical imaging technology, which has been integrated with SpectraCure's IDOSE[®] system, is approved by the Food and Drug Administration (FDA) for use in the clinical study in the US. The integration makes the treatment more efficient and facilitates the process. In December 2021 a development project, partially funded by EU, was completed together […]
SpectraCure has been approved a grant from EU of € 125,000
SpectraCure has been approved a grant from EU of € 125,000 for an industrialization project for the company's product, for the treatment of prostate cancer with interstitial photodynamic treatment (PDT). The grant is approved as part of MedPhab, a so-called "pilot production line", financed through grants from the EU's Horizon 2020 program. In the project, […]
Patent approved in Europe
SpectraCure's patent application for a new technology, to improve the company's IDOSE® technology, has been approved by the European Patent Office, EPO. The IDOSE® technology is central to SpectraCure's method of treating prostate cancer with photodynamic tumor therapy (PDT). In short, IDOSE® technology means that the prostate tissue is monitored during treatment with a series […]
A new Board has been installed at SpectraCure
CEO Johan Folkunger together with parts of the board. Following Thursday's Annual General Meeting, a new Board of Directors has been installed at SpectraCure. The Board is intended to reflect the Company's development stage. Jörgen Wennberg, former CEO of ICA Bank, is the new Chairman of the Board. Homer Pien and Katarina Svanberg were re-elected […]
